Lunit has announced a strategic partnership with Selcarta to accelerate the commercialization of AI-based biomarkers for companion diagnostics.
The collaboration expands on an earlier agreement to integrate Lunit’s AI biomarker platform, Lunit Scope, into Selcarta’s global clinical trial framework. The new deal focuses on advancing CDx development, supporting product launches, and scaling global commercialization.
Lunit Scope will be embedded into Selcarta’s clinical workflows, enabling biomarker strategy development, immunohistochemistry analysis, immune profiling, and CDx preparation. The goal is to streamline trial processes, helping drug developers enter clinical stages faster and shorten timelines for diagnostic launches.
The companies also plan to roll out a global pilot program to expand AI use across all phases of clinical trials.
Selcarta CEO Dusty Tenney said the partnership aims to improve both speed and quality in drug development. Lunit CEO added that real-world scalability is key to broader AI adoption in the pharmaceutical industry.